Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Rubella vaccine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    76 result(s) found for: Rubella vaccine. Displaying page 4 of 4.
    « Previous 1  2  3  4 
    EudraCT Number: 2018-004109-21 Sponsor Protocol Number: V114-029 Start Date*: 2021-06-10
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants (PNEU-PED)
    Medical condition: Prevention of pneumococcal disease associated with serotypes included in the vaccine.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10061353 Pneumococcal infection PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-006066-34 Sponsor Protocol Number: 105987,105988 Start Date*: 2015-06-01
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, single-blind, randomized, controlled, multinational study for the evaluation of safety of GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-t...
    Medical condition: Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004862 10028911 Neisseria meningitidis infection NOS LLT
    18.0 100000004862 10018953 Haemophilus influenzae meningitis LLT
    18.0 100000004862 10018952 Haemophilus influenzae infection LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-004433-14 Sponsor Protocol Number: A3L15 Start Date*: 2012-04-10
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Randomized, open, controlled, multicenter, Phase III trial in infants who will receive DTaP-IPV-Hep B-PRP-T (Group 1, N=286), CombAct-Hib™ and Engerix B™ Pediatric with OPV (Group 2, N=286), or DTa...
    Medical condition: Prevention of infections caused by Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, poliovirus types 1, 2 and 3, prevention against invasive infections caused by Haemophilus i...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10021430 Immunisation PT
    14.1 10042613 - Surgical and medical procedures 10036897 Prophylactic vaccination LLT
    14.1 10042613 - Surgical and medical procedures 10021431 Immunisations HLT
    14.1 10042613 - Surgical and medical procedures 10043413 Therapeutic procedures and supportive care NEC HLGT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-002946-11 Sponsor Protocol Number: 111852 Start Date*: 2015-05-22
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IIIb, open label, randomized, multicenter study of the im-munogenicity and safety of a booster dose of Kinrix when co-administered with varicella vaccine (Varivax®, Merck and Company) and M...
    Medical condition: Booster immunization of healthy children 4-6 years of age against diphtheria, tetanus, pertussis and polio diseases.
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-004541-33 Sponsor Protocol Number: immvzmpr1 Start Date*: Information not available in EudraCT
    Sponsor Name:Västra Götalandsregionen
    Full Title: A clinical study to examine cellular and humoral immunity against measles and chickenpox in children and adolescents 0-18 years in childhood cancer.
    Medical condition: This study will be conducted as a longitudinal study. Former studies have shown that immunity is affected after treatment against childhood cancer. We want to investigate humoral and cell-mediated ...
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-003268-37 Sponsor Protocol Number: 205239 Start Date*: 2018-09-26
    Sponsor Name:GlaxoSmithKline Biologicals SA
    Full Title: A Phase IIIB, Observer-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine when...
    Medical condition: Healthy subjects (to assess the safety and immunogenicity of Bexsero and Prevnar13 when administered concomitantly with RIV to healthy infants).
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2009-011523-31 Sponsor Protocol Number: 09/H0720/64 Start Date*: 2009-06-23
    Sponsor Name:R & D, Cambridge University Hospitals
    Full Title: A study of the immune response to vaccination in MS patients treated with alemtuzumab
    Medical condition: The vaccinations are being used to investigate immunological memory following treatment of multiple sclerosis with the lympho-depleting humanised monoclonal antibody alemtuzumab.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis PT
    9.1 10063400 Secondary progressive multiple sclerosis PT
    9.1 10046859 Vaccination LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-006301-17 Sponsor Protocol Number: V72P13E1 Start Date*: 2009-01-20
    Sponsor Name:NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.
    Full Title: A Phase 3, Open label, Multi-Center, Extension Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster at 12 Mon...
    Medical condition: Demonstration of a sufficient immune response following a fourth (booster) dose of rMenB+OMV NZ administered at 12 months of age, either with or without concomitant MMRV vaccination, to toddlers pr...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027249 Meningitis meningococcal LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed) CZ (Completed) FI (Completed) DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-000304-32 Sponsor Protocol Number: 6096A1-3007 Start Date*: 2007-05-28
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc
    Full Title: Estudio fase 3, randomizado, controlado, doble ciego para evaluar la seguridad, tolerabilidad e inmunogenicidad de la Vacuna Neumocócica Conjugada 13-valente en niños sanos administrada con la vac...
    Medical condition: Healthy infants - Niños sanos
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-012059-47 Sponsor Protocol Number: IFN-K-001 Start Date*: 2010-01-28
    Sponsor Name:Neovacs SA
    Full Title: A phase I-II, randomized, double-blind, placebo-controlled, dose escalation study of Neovacs’ IFNα-Kinoid in adult subjects with Systemic Lupus Erythematosus.
    Medical condition: Systemic Lupus Erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) FR (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002413-11 Sponsor Protocol Number: PRI01C Start Date*: 2012-02-07
    Sponsor Name:Sanofi Pasteur MSD S.N.C
    Full Title: A phase III open-label randomised study, to evaluate the immunogenicity and safety of the concomitant administration of V419 (PR5I) given at 2, 3 and 4 months of age with two types of meningococcal...
    Medical condition: PR5I is developed to provide active immunization against diphtheria, tetanus, pertussis, poliomyelitis (caused by poliovirus Types 1, 2 and 3), invasive disease caused by Haemophilus influenza ty...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10054183 Tetanus immunization LLT
    14.1 10022891 - Investigations 10019743 Hepatitis B virus (HBV) LLT
    14.1 10042613 - Surgical and medical procedures 10054181 Hepatitis B immunization LLT
    14.1 10042613 - Surgical and medical procedures 10069593 Pertussis immunization LLT
    14.1 10042613 - Surgical and medical procedures 10054180 Diphtheria immunization LLT
    14.1 10042613 - Surgical and medical procedures 10053386 Poliomyelitis vaccine LLT
    14.1 10042613 - Surgical and medical procedures 10069543 Hemophilus influenzae type b immunization LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2023-000945-18 Sponsor Protocol Number: 219449 Start Date*: 2024-10-28
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase 2 single-blind, randomized, controlled, single center study to assess the immunogenicity and safety of a 2-dose schedule with GVGH altSonflex1-2-3 vaccine in African infants (H06_02TP)
    Medical condition: Prophylaxis for Shigellosis induced by Shigella sonnei, Shigella flexneri 1b, Shigella flexneri 2a and Shigella flexneri 3a.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10040550 Shigella infections HLT
    27.1 10021881 - Infections and infestations 10054178 Shigella infection PT
    20.0 10021881 - Infections and infestations 10040542 Shigella LLT
    20.0 10021881 - Infections and infestations 10040547 Shigella flexneri LLT
    20.0 10021881 - Infections and infestations 10040551 Shigella sonnei LLT
    20.1 10021881 - Infections and infestations 10004016 Bacterial diarrhoea PT
    20.0 10017947 - Gastrointestinal disorders 10012735 Diarrhoea PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2006-006204-11 Sponsor Protocol Number: 6096A1-3000 Start Date*: Information not available in EudraCT
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc.
    Full Title: A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Manufacturing Scale 13-valent Pneumococcal Conjugate Vaccine
    Medical condition: Healthy infants
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: PL (Ongoing)
    Trial results: View results
    EudraCT Number: 2010-021490-37 Sponsor Protocol Number: V419-007 Start Date*: 2011-03-09
    Sponsor Name:Sanofi Pasteur MSD
    Full Title: A Phase III Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4, and 12 Months.
    Medical condition: PR5I is developed to provide active immunization against diphtheria, tetanus, pertussis, poliomyelitis (caused by poliovirus Types 1, 2 and 3), invasive disease caused by Haemophilus influenza type...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10054130 Hepatitis B immunisation PT
    14.1 10042613 - Surgical and medical procedures 10054129 Diphtheria immunisation PT
    14.1 10042613 - Surgical and medical procedures 10053386 Poliomyelitis vaccine LLT
    14.1 10042613 - Surgical and medical procedures 10069543 Hemophilus influenzae type b immunization LLT
    14.1 10042613 - Surgical and medical procedures 10069577 Pertussis immunisation PT
    14.1 10021881 - Infections and infestations 10019731 Hepatitis B PT
    14.1 10042613 - Surgical and medical procedures 10054131 Tetanus immunisation PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) FI (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-000891-12 Sponsor Protocol Number: 212149 Start Date*: 2021-10-05
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A staged Phase I/II observer-blind, randomised, controlled, multi-country study to evaluate the safety, reactogenicity, and immune responses to the GVGH altSonflex1-2-3 vaccine against S. sonnei an...
    Medical condition: Prophylaxis for Shigellosis induced by Shigella sonnei, Shigella flexneri 1b, Shigella flexneri 2a and Shigella flexneri 3a.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10040550 Shigella infections HLT
    20.0 10021881 - Infections and infestations 10054178 Shigella infection PT
    20.0 10021881 - Infections and infestations 10040542 Shigella LLT
    20.0 10021881 - Infections and infestations 10040547 Shigella flexneri LLT
    20.0 10021881 - Infections and infestations 10040551 Shigella sonnei LLT
    20.1 10021881 - Infections and infestations 10004016 Bacterial diarrhoea PT
    20.0 10017947 - Gastrointestinal disorders 10012735 Diarrhoea PT
    Population Age: Infants and toddlers, Children, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004958-42 Sponsor Protocol Number: MOM-M281-003 Start Date*: 2019-01-11
    Sponsor Name:Momenta Pharmaceuticals, Inc.
    Full Title: A Multicenter, Open-Label Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease ...
    Medical condition: Early onset Severe Hemolytic Disease of the fetus and newborn (HDFN)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10019512 Hemolytic disease due to Rh isoimmunization of fetus or newborn LLT
    Population Age: In utero, Under 18, Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) NL (Completed) SE (Completed) ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 15 06:16:31 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA